Article

Inhibition of Src Family Kinases Ameliorates LPS-Induced Acute Kidney Injury and Mitochondrial Dysfunction in Mice

Eun Seon Pak, Md Jamal Uddin* and Hunjoo Ha *

Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul 03760, Korea; louisa9419@gmail.com (E.S.P.); hasan800920@gmail.com (M.J.U.)
* Correspondence: hha@ewha.ac.kr; Tel.: +82-2-3277-4075; Fax: +82-2-3277-2851

Received: 16 October 2020; Accepted: 2 November 2020; Published: 3 November 2020

Abstract: Acute kidney injury (AKI), a critical syndrome characterized by a rapid decrease of kidney function, is a global health problem. Src family kinases (SFK) are proto-oncogenes that regulate diverse biological functions including mitochondrial function. Since mitochondrial dysfunction plays an important role in the development of AKI, and since unbalanced SFK activity causes mitochondrial dysfunction, the present study examined the role of SFK in AKI. Lipopolysaccharides (LPS) inhibited mitochondrial biogenesis and upregulated the expression of NGAL, a marker of tubular epithelial cell injury, in mouse proximal tubular epithelial (mProx) cells. These alterations were prevented by PP2, a pan SFK inhibitor. Importantly, PP2 pretreatment significantly ameliorated LPS-induced loss of kidney function and injury including inflammation and oxidative stress. The attenuation of LPS-induced AKI by PP2 was accompanied by the maintenance of mitochondrial biogenesis. LPS upregulated SFK, especially Fyn and Src, in mouse kidney as well as in mProx cells. These data suggest that Fyn and Src kinases are involved in the pathogenesis of LPS-induced AKI, and that inhibition of Fyn and Src kinases may have a potential therapeutic effect, possibly via improving mitochondrial biogenesis.

Keywords: acute kidney injury; inflammation; mitochondrial biogenesis; oxidative stress; Src family kinases inhibitor

1. Introduction

Acute kidney injury (AKI) is defined by a rapid increase in serum creatinine (≥1.5 times the baseline within 7 days) or a rapid decrease in urine volume (<0.5 mL/kg/h for 6 h) [1]. Numerous studies have shown that AKI is associated with high morbidity and mortality in critically ill patients, and with high healthcare costs [2,3]. In addition, AKI can contribute to the progression of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) [4]. The pathophysiology of AKI is multifactorial and involves inflammation, tubular injury, and vascular damage [5–7]. Since many targeted clinical trials for AKI have failed [8,9], discovering the detailed pathogenic mechanism and developing novel therapeutic agents is essential.

The Src family of kinases (SFK), non-receptor tyrosine kinases, is comprised of Fyn, Src, Yes, Lyn, Fgr, Lck, Hck, Blk, and Yrk. All members contribute to many aspects of cellular function including proliferation, survival, adhesion, migration, invasion, and metabolism [10]. SFK are widely expressed in a variety of tissues [11], particularly under pathologic conditions [12].

SFK expressed in the kidney play a role in the pathogenesis of kidney dysfunction. Src and Fyn kinases have been shown to be related to diabetic kidney disease [13,14] and unilateral ureteral obstruction (UO)-induced tubulointerstitial fibrosis [15,16], respectively. Pharmacological inhibition
of SFK using PP2 [13–16] and SU-6656 [13,14] have been effective in treating CKD in vivo and in vitro. We have recently reviewed the possible role of Fyn in AKI [17]. Although the evidence is limited, one study has shown that an SFK inhibitor, PP1, is effective in attenuating AKI induced by ischemia/reperfusion (I/R) [18]. However, the detailed mechanism of SFK in AKI remains elusive.

Mitochondria are important organelles that supply cellular energy [19]. Both mitochondrial function and biogenesis are associated with their morphology, number, and localization/positioning [20]. Alterations in mitochondrial function or biogenesis play a critical role in various pathological conditions [21]. The kidney is one of the most energy-demanding organs and it is rich in mitochondrial content [22]. Previous studies have demonstrated that mitochondrial dysfunction is a critical contributor to the pathogenesis of AKI [23,24]. The expression of PPARγ coactivator-1α (PGC-1α), a master regulator of mitochondrial biogenesis [25], is negatively associated with kidney injury during AKI [26]. TNF-α reduced PGC-1α expression and mitochondrial oxygen consumption in human proximal tubular epithelial cells, which was reversed by PGC-1α overexpression [26]. Global and proximal tubule specific PGC-1α depletion retarded the recovery from lipopolysaccharides (LPS)-induced kidney injury in mice [26].

Interestingly, SFK regulates mitochondrial tyrosine phosphorylation [27,28] and oxidative phosphorylation (OXPHOS) [29,30]. Src overexpression impairs mitochondrial OXPHOS in HepG cells, which is recovered by PP2 [30]. The role of SFK on mitochondrial biogenesis in AKI has not been reported.

The present study examined whether SFK plays a role in AKI through dysregulation of mitochondria. LPS was used to induce AKI in C57BL/6 mice as well as in mouse proximal tubular epithelial (mProx) cells, the major site of AKI. PP2, a pan SFK inhibitor, was used to determine the involvement of SFK.

2. Results

2.1. PP2 Ameliorates LPS-Induced Mitochondrial Dysfunction and Tubular Injury in mProx Cells

We first determined the effect of PP2 on LPS-induced dysregulation of mitochondrial biogenesis in mProx cells. As expected, the mRNA expression of PGC-1α, a master regulator of mitochondrial biogenesis, was decreased by 78% as early as 3 h after LPS exposure and was persistently reduced for up to 24 h (Figure 1A). The mRNA expression of other markers of mitochondrial fitness including TFAM, Nrf1, mtDNA, and CytB were also decreased in response to LPS (Figure 1A). Pretreatment of PP2 at 10 μM effectively restored the LPS-induced suppression of PGC-1α, TFAM, Nrf1, mtDNA, and CytB mRNA expression in the cells (Figure 1B). Mitochondria stained by MitoTracker were also decreased in response to LPS, which was effectively prevented by PP2 in a dose-dependent manner (Figure 1C). LPS upregulated mRNA levels of NGAL, a marker of tubular epithelial cell injury, which was significantly attenuated by PP2 in a dose-dependent manner (Figure 1D,E).
Figure 1. PP2 maintains mitochondrial biogenesis in mProx cells. (A,D) The mProx cells were stimulated with lipopolysaccharides (LPS) in a time-dependent manner (0, 3, 6, 12, and 24 h). (A) The mRNA levels of mitochondrial fitness markers such as PGC-1α, TFAM, Nrf1, mtDNA, and CytB were measured. (B,C,E) The cells were pretreated with PP2 (0, 1, 5, and 10 µM) for 2 h and then stimulated with LPS (100 ng/mL) for 9 h. (B) The mRNA levels of PGC-1α, TFAM, Nrf1, mtDNA, and CytB were measured. (C) The mitochondria in mProx cells were labeled with MitoTracker staining. (D) The mRNA levels of NGAL were measured in mProx cells after LPS (100 ng/mL) stimulation in a time-dependent manner (0, 3, 6, 12, and 24 h). (E) The mRNA levels of NGAL were measured. The levels of mRNA expression were measured using real-time RT-PCR analysis and normalized with 18S. Data are presented as mean ± SE, n = 4. * p < 0.05 vs. control. † p < 0.05 vs. LPS.

2.2. PP2 Improves Kidney Function and Attenuates Kidney Tubular Injury in LPS-Induced AKI

We next examined the kidney tubular epithelial cell injury in mice after LPS exposure. The expression of NGAL mRNA was increased in the kidneys after LPS exposure for up to 24 h (Figure S2). To examine the effect of PP2 on kidney function and the morphology changes in LPS-induced AKI, we collected blood and kidney samples after 18 h of LPS administration. The kidney injury markers such as plasma creatinine and cystatin C were elevated in response to LPS, which was prevented by PP2 (Figure 2A,B). Then, we determined that the tubular injury as measured by plasma KIM-1 and NGAL immunostaining was also increased in response to LPS, which was prevented by PP2 (Figure 2C–E). PAS staining showed a clear increase in tubular injury in response to LPS, which was
ameliorated by PP2 (Figure 2F). Tubular cell apoptosis indicated by TUNEL staining was increased in LPS-induced AKI mice and this was decreased by pretreatment with PP2 (Figure 2G).

**Figure 2.** PP2 improves kidney function and attenuates kidney tubular injury in LPS-induced acute kidney injury (AKI) mice. Blood plasma was analyzed for (A) plasma creatinine (mg/dL), (B) plasma cystatin C (ng/mL), and (C) tubular injury marker, plasma Kim1 (pg/mL). Paraffin-embedded kidney sections were stained with (D,E) NGAL antibody (1:200; original magnification: 200×; scale bar: 100 µm; enlarged images have been shown in inset) and (F) PAS staining (original magnification: 630×; scale bar: 20 µm). (G) Apoptosis was measured in kidney sections using the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay (original magnification: 400×; scale bar: 100 µm). Data are presented as mean ±SE of 6–8 mice. *p < 0.05 vs. control, †p < 0.05 vs. LPS.
2.3. PP2 Ameliorates Inflammation in LPS-Induced AKI

Inflammation is critically involved in AKI. In order to determine whether PP2 has an anti-inflammatory effect, we evaluated the expression of proinflammatory cytokines in AKI mice. LPS increased the mRNA expression of tumor necrosis factor-α (TNF-α), inducible nitric oxide synthase (iNOS), and intracellular adhesion molecule-1 (ICAM-1) in AKI mice, which were all alleviated by PP2 (Figure 3A–C). In addition, macrophage infiltration as measured by F4/80 staining was also increased in response to LPS, whereas pretreatment with PP2 decreased these effects (Figure 3D,E).

Figure 3. PP2 inhibits kidney inflammation in the LPS-induced AKI mice. (A–C) The mRNA levels of inflammation markers such as TNF-α, iNOS, and ICAM1 in kidney tissue were measured using real time RT-PCR analysis. The levels of mRNA were normalized with 18S. (D,E) Paraffin-embedded kidney sections were stained with anti-F4/80 antibody (1:400; original magnification: 200×; scale bar: 100 µm). Data are presented as mean ±SE of 6–8 mice. * p < 0.05 vs. control, † p < 0.05 vs. LPS.

2.4. PP2 Attenuates Oxidative Stress in LPS-Induced AKI

We evaluated the state of oxidative stress in AKI mice through the use of the lipid hydroperoxide (LPO) assay in plasma samples and through 8-oxo-dG immunostaining of kidney tissues. LPS increased the LPO concentration and 8-oxo-dG expression, which were all attenuated by PP2 (Figure 4A–C). DHE staining was performed to directly measure the reactive oxygen species (ROS) in the kidney tissue. LPS effectively induced the ROS level, which was reduced by PP2 (Figure 4D). In addition, the expression of Nox2 and Nox4 as measured by immunostaining were increased in response to LPS, and were reduced by PP2 (Figure 4E–H).
Figure 4. PP2 attenuates kidney oxidative stress in the LPS-induced AKI mice.  
(A) Plasma lipid hydroperoxide (LPO) (µM). (B,C) Paraffin-embedded kidney sections were stained with 8-oxo-dG (1:200; original magnification: 100×; scale bar: 200 µm) antibody. (D) Frozen kidney sections were stained with DHE dye (5 µM for 10 min; original magnification: 100×; scale bar: 50 µm). (E–H) Paraffin-embedded kidney sections were stained with Nox2 (1:500; original magnification: 200×; scale bar: 100 µm) and Nox4 (1:400; original magnification: 200×; scale bar: 100 µm) antibodies. Data are presented as mean ±SE of 6–8 mice. * p < 0.05 vs. control, † p < 0.05 vs. LPS.
2.5. SFK, Mainly Fyn and Src, Are Increased in LPS-Induced AKI

We examined the levels of SFK in the kidney after LPS injury. Interestingly, mRNA expression of SFK, i.e., Fyn and Src, were increased in the kidneys after LPS exposure for up to 24 h (Figure 5A). Similarly, the expression of Fyn and Src mRNA was increased in the mProx cells in response to LPS (Figure S1). Pretreatment with PP2 decreased the LPS-induced upregulation of Fyn and Src mRNA expression in the kidneys (Figure 5B). In addition, phosphorylation of Fyn (p-Fyn) and Src (p-Src) was upregulated in response to LPS, which was blocked by pretreatment with PP2 (Figure 6A–H). Increased p-Fyn and p-Src expression in response to LPS were also confirmed by immunofluorescence staining, and these levels were decreased by the pretreatment with PP2 (Figure 6I).

Figure 5. LPS increases Src family kinases (SFK) mRNA expression in AKI mice. (A) Six-week-old male C57/BL6 mice were treated with LPS (15 mg/kg) in a time-dependent manner (0, 6, 12, and 24 h). (B) Six-week-old male C57/BL6 mice were pretreated with PP2 (2 mg/kg) for 2 h and then administered LPS (15 mg/kg) for 18 h. (A, B) The levels of SFK mRNA expression were measured using real-time RT-PCR analysis. Levels of mRNA were normalized with 18S. Data are presented as mean ±SE of 6–8 mice. * p < 0.05 vs. control, † p < 0.05 vs. LPS.
Figure 6. PP2 inhibits Src and Fyn kinase expression in LPS-induced AKI mice. Six-week-old male C57/BL6 mice were pretreated with PP2 (2 mg/kg) for 2 h and then administered LPS (15 mg/kg) for 18 h. (A–H) Immunoblotting analysis of phosphorylated/total Fyn and Src kinase in the kidney. Levels of proteins were normalized to their respective total protein. (I) Kidney sections were subjected for immunofluorescence staining with phospho-Fyn (red) and phospho-Src (green) antibodies and 4',6-diamidino-2-phenylindole (DAPI; blue). Data are presented as mean ± SE of 6–8 mice. * $p < 0.05$ vs. control, † $p < 0.05$ vs. LPS.

2.6. PP2 Attenuates Mitochondrial Dysfunction in LPS-Induced AKI

We measured the expression of mitochondrial fitness markers in the kidneys of LPS-induced AKI mice. LPS reduced the mRNA expression levels of mtDNA, CytB, Cox4i1, and Crif1 in AKI mice, which were all prevented by PP2 (Figure 7A). In addition, the protein expression of PGC-1α TFAM, Nrf1, and Cox4i1 were also reduced in LPS-induced AKI mice (Figure 7B–G). Pretreatment with PP2 effectively restored LPS-induced suppression of PGC-1α TFAM, Nrf1, and Cox4i1 protein expression in the kidneys of AKI mice (Figure 7B–G).
Figure 7. PP2 preserves mitochondrial biogenesis in LPS-induced AKI mice. (A–G) Six-week-old male C57/BL6 mice were pretreated with PP2 (2 mg/kg) for 2 h and then administered LPS (15 mg/kg) for 18 h. (A) The mRNA levels of mtDNA, CytB, Cox4i1, and Crif1 in kidney tissue were measured using real time RT-PCR analysis. The levels of mRNA were normalized with 18S. (B–C) Paraﬁn-embedded kidney sections were stained with PGC-1α antibody (1:200; original magnification: 200×; scale bar: 100 µm). Immunoblotting analysis of (D) PGC-1α, (E) TFAM, (F) Nrf1, and (G) Cox4i1 in the kidney was performed. The levels of proteins were normalized with HSC70 and β-actin. Data are presented as mean ±SE of 6–8 mice * p < 0.05 vs. control, † p < 0.05 vs. LPS.

3. Discussion

In the present study, we demonstrated that (i) inhibition of SFK ameliorated LPS-induced kidney injury and mitochondrial dysfunction, and (ii) the expression and activation of Fyn and Src were increased in LPS-induced AKI.

SFK have been discovered to play important roles in cancer biology including the regulation of cell growth, differentiation, metabolism, and apoptosis [10]. In addition, SFK have long been recognized to participate in pathological conditions related to inflammatory responses [31]. Recent studies have also suggested a possible role of SFK in kidney diseases [14–16,18,32].

The sepsis-induced AKI is characterized by parenchymal inflammation, endothelial dysfunction, intra-glomerular thrombosis, and tubular injury [5–7]. The endothelium is the primary target of endotoxin, and endothelial dysfunction is considered as a key player leading to exacerbated inflammatory response and kidney failure [6,7]. In addition, LPS induced pathological
ultrastructural changes of mitochondria in both renal tubular epithelial cells and the endothelial cells, and mitochondrial-targeted antioxidants protected LPS-induced AKI [33].

We first confirmed that LPS induces kidney dysfunction, estimated by plasma creatinine and cystatin C, and kidney injury, including inflammation and oxidative stress, in the proximal tubular epithelial cells. In agreement with previous studies that showed mitochondrial dysfunction in AKI [23,24,26], mRNA expression of PGC-1α as well as other markers of mitochondrial fitness including TFMA, Nrf1, mtDNA, and CytB were decreased in response to LPS. PGC-1α is an important regulator of mitochondrial biogenesis in organs with high energy demands, including the kidney [25]. Importantly, pretreatment with PP2 effectively attenuated LPS-induced suppression of mitochondrial biogenesis markers in mProx cells and AKI mice, as well as decreasing the level of mitochondria staining by MitoTracker in mProx cells.

In line with our data, overexpression of Src impaired mitochondrial energy metabolism via regulating OXPHOS in HepG cells. The decrease in the OXPHOS complex was, as expected, increased by PP2 [30]. SFK are not only constitutively expressed in the mitochondria [27] but can also be translocated into the mitochondria from the cytoplasm, a process that is dependent on EGFR [34], AKAP121 [35], and Dok-4 [36]. Although the pharmacologic inhibition of SFK improved mitochondrial biogenesis in LPS-induced AKI, the detailed mechanisms and functional link between SFK and dysregulation of mitochondrial biogenesis remains to be studied.

Pretreatment with PP2 inhibited the increases in plasma creatinine and cystatin C normally found in LPS-induced AKI mice. In addition, PP2 pretreatment effectively protected against LPS-induced kidney inflammation and oxidative stress. Inflammation is an important component in the establishment of AKI [37]. Infiltrating macrophages exacerbate kidney injury by producing high levels of cytokines such as TNF-α and ICAM-1 [38]. Similar to our observations, the genetic modification and pharmacological inhibition of SFK attenuated inflammatory responses in ischemic brain injury [39] and acute lung injury [40].

SFK are activated under oxidative stress [41], and the cysteine residues of SFK are redox sensitive [42]. Oxidation of the residues such as Cys245 and Cys487 causes a conformational change that contributes to the activation of SFK [42]. Conversely, inhibition of Src by PP2 attenuates hypoxia-mediated ROS through the inhibition of NADPH oxidase [43]. These studies suggest that SFK are activated by oxidative stress through direct oxidation of structural domains [42] and SFK may also act upstream of NADPH oxidase, thereby contributing to increased oxidative stress [43].

Although limited, previous studies have shown that Src was activated in I/R-induced AKI [18,44], while Fyn was increased in UUO-induced CKD [15]. Among the eight family members, only the levels of Fyn and Src expression were elevated as early as 6 h after LPS administration to mice and mProx cells. LPS-induced activation of Fyn and Src were inhibited by pretreatment with PP2. Interestingly, our study showed that not only phosphorylation but also transcription and total protein level were increased in LPS-induced AKI, which were alleviated by PP2. Although PP2 decreased the transcription and total protein level under our experimental conditions, the detailed mechanisms involved are not clear.

Several questions related to our findings remain to be answered. First, considering that Src activation is an immediate downstream target of TLR4 activation [45,46], the preservation of mitochondrial biogenesis could be a result of decreasing LPS signaling rather than a direct effect of the Src inhibition. To clearly show the functional link between SFK and mitochondria biogenesis, it is necessary to perform experiments on kidneys with selective overexpression of SFK as well as mitochondrial biogenesis molecules. Second, considering the clinical implication, further studies on therapeutic effects of PP2 in AKI are needed. Third, considering the role of endothelial damage in AKI, the role of SFK in the endothelial compartment warrants further study.
4. Materials and Methods

4.1. Reagents

All chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified.

4.2. Cell Culture

The mProx cells were provided by Dr. Takeshi Sugaya (St. Marianna University School of Medicine, Kanagawa, Japan) and cultured as described [47]. Briefly, the cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA, USA) containing 10% bovine serum (BCS; GIBCO by Life Technologies, Carlsbad, CA, USA), 100 U/mL penicillin, 100 µg/mL streptomycin, 20 mM glucose, and 44 mM NaHCO₃ under a 5% CO₂ environment at 37 °C. The cells (5 × 10⁵ cells/well) were seeded in 6-well plates. Sub-confluent cells were allowed to growth-arrest with DMEM containing 1% BCS for 18 h before starting the experiments. The cells were pretreated with PP2 (0, 1, 5, and 10 µM, dissolved in dimethyl sulfoxide (DMSO)) for 2 h and then stimulated with LPS (100 ng/mL, dissolved in distilled water) for 9 h.

4.3. Animals

All experimental animals were approved by the Institutional Animal Care and Use Committee at Ewha Womans University (Approval number: IACUC No. 16-055, 12 October 2016). Six-week-old male C57BL/6 mice (Japan SLC Inc., Hamamatsu, Japan) were used. Mice were randomly divided into four groups: (i) control, (ii) LPS 6 h, (iii) LPS 12 h, and (iv) LPS 24 h. Mice were examined for the induction of AKI at 6, 12, and 24 h using a single intraperitoneal (i.p.) injection of LPS (15 mg/kg).

In another set of experiments, mice were also divided into four groups: (i) control, (ii) PP2, (iii) LPS, and (iv) LPS treated with PP2. AKI induction was confirmed by single i.p. injection of LPS (15 mg/kg) for 18 h. Control mice were administrated with an equivalent volume of saline as the vehicle of LPS. PP2 (2 mg/kg) was administered (i.p.) to the mice 2 h before the injection (i.p.) of LPS, and control mice were injected with an equivalent volume of DMSO as the vehicle of PP2. All mice were sacrificed at the above time points after injection of LPS.

4.4. Measurements of Blood Parameters

Blood was centrifuged at 3000 rpm for 15 min at 4 °C, and plasma was collected. Plasma creatinine (Arbor Assays, Ann Arbor, MI, USA), plasma cystatin C (MSCTC0, R&D Systems, Minneapolis, MN, USA), and plasma kidney injury molecule-1 (KIM-1, MKM100, R&D Systems) were determined by using ELISA kits according to the manufacturer’s instructions. Plasma lipid hydroperoxide (LPO) level was measured by a reaction with thiobarbituric acid as described previously [48]. The experiments were performed in duplicate.

4.5. Histology and Immunohistochemistry

The right kidneys were fixed with 2% paraformaldehyde-lysine-periodate, pH 7.4, dehydrated, embedded in paraffin, and sectioned. Kidneys were stained with periodic acid—Schiff (PAS) reagent. Immunohistochemistry was performed using anti-neutrophil gelatinase-associated lipocalin (anti-NGAL, 1:200; Abcam, Cambridge, MA, USA), anti-F4/80 (1:400; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), anti-8-hydroxy-2-deoxyguanosine (8-oxo-dG, 1:200; Trevigen, Gaithersburg, MD, USA), anti-NADPH oxidase 2 (Nox2, 1:500; Gifted by Professor Yun Soo Bae, Department of Life Science, College of Natural Sciences, Ewha Womans University, Seoul, Korea), anti-NADPH oxidase 4 (Nox4, 1:300; Gifted by Professor Yun Soo Bae), and anti-PPARγ coactivator-1α (PGC-1α, 1:200; Abcam) primary antibodies. Images were obtained by light microscopy (Carl Zeiss Microscopy, GmbH, 07745, Jena, Germany) and analyzed using ImagePro 3.5 software.
4.6. Immunofluorescence Staining

After deparaffinization and rehydration, kidney tissue sections were incubated with antigen retrieval solution and heated in a microwave to recover antigenicity. Non-specific binding was blocked with serum-free blocking solution for 30 min at room temperature. The sections were then incubated with anti-p-Fyn (1:100; Santa Cruz Biotechnology) and anti-p-Src (1:100; Cell Signaling Technology, Denver, MA, USA) overnight at 4 °C. Then, the sections were incubated for 1 h with Alexa 488-conjugated goat anti-mouse (1:1000; Invitrogen) or Alexa 568-conjugated goat anti rabbit (1:1000; Invitrogen) antibody. Cell nuclei were detected with 4',6-diamidino-2-phenylindole (DAPI, 1:1000; Thermo Fisher Scientific, Waltham, MA, USA). Images were captured by a Zeiss ApoTome Axiovert 200M microscope (Carl Zeiss Microscopy).

4.7. Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)

Total RNA was isolated using TRIzol reagent (Invitrogen) as described [49]. Total RNA was used to synthesize cDNA. The resulting cDNA was subjected to real-time PCR using an ABI7300 (Applied Biosystems, Carlsbad, CA, USA). Expression levels of the mRNAs were measured by real-time PCR with 20 µL reaction volume consisting of cDNA transcripts, primer pairs, SYBR Green, and PCR Master Mix (Applied Biosystems). The primer sequences are listed in Table 1. The genes were normalized using 18S as an internal control.

Table 1. Primer sequences used for real time RT-PCR analysis.

| Gene   | Forward (5′→3′)               | Reverse (5′→3′)              |
|--------|-------------------------------|-------------------------------|
| 18S    | CGAAAGCATTTTGCCAAGAAAT        | AGTCGCCATCGTTATGTC            |
| Cox4i1 | TCGATCTGTACTGGTGCGCCA         | GCCGAGGGATGAGAGGAGGC          |
| Crif1  | AGCTAACGCCCTGGGTATTTGCA       | CTGTCAATGCCAGTGATGCCCG        |
| CytB   | AAGACACCCTGGGTACCTTGCA        | TCTGCTTGAGATGATCAA            |
| Fyn    | CTTTGGGCTGGTGAACCTCTT         | TCGAAGGAGGAGAGGAGGC           |
| Hck    | AGGAGTTAGAAGTGGGAACA          | CCCAGAGATTGGACCCCC            |
| ICAM-1 | CTTCAGCTACCACATGCAAA          | CTTCAAGGAGGAGGAAAAAGG         |
| iNOS   | GGACAGCTGTAGAGACCTTTTG        | ATTGGAAGTGAAGGTTTCC           |
| Lck    | AGCATCTGGGGGATCTAGGG          | GAGATCTGTGCTGCTGAGGGGG        |
| Lyn    | AGCTCCAGAGGGCAGCAA          | CACATCAGTGTTGCTTC             |
| mtDNA  | CCACCTCATCTTACATTTA           | ATCTGATCTGATTTAAAA            |
| NGAL   | GGCGCATCTCCTGGGAGAAAA         | TGGCGAAACTTTGTTGAGCCCC        |
| NRF-1  | CAACAGGGAGAAGAAGGAAAA         | GACACCACTACCTCAAAGGGT         |
| PGC-1α | TCAGTGTGCTGCCCTTCTTG          | AGGAGACGGCATCCTTTGGG          |
| Src    | TCCACACTCCCTCGCGAAGCAA        | CATGCTGATGCGCTGTGCCGA         |
| TFAM   | ATTCGCGAGTTTCTTTCAGCA         | TCTGCGAACCTGCTCTGAGGT         |
| TNF-α  | CTTCAAGGAGGAGGAGGAAA          | CAGACTCGGACCAAGCTCAAG         |
| Yes    | TGGGAAATCGAGGAGGTTA          | ACATGTCACCTACCCCTCACCT        |

4.8. Western Blot Analysis

Whole kidney protein was extracted with lysis buffer. After centrifugation (13,000 rpm, 4 °C, 15 min), the lysate was mixed with 5x sample buffer and heated at 95 °C for 6 min. Total protein concentrations were measured using Bradford methods (BioRad Laboratories, Hercules, CA, USA). The lysate was subjected to SDS-PAGE gel electrophoresis and transferred onto a polyvinylidene difluoride (PVDF) membrane. The PVDF membranes were incubated overnight at 4 °C with the primary antibodies: anti-p-Src (1:1000; Cell Signaling Technology), anti-p-Fyn (1:1000; Santa Cruz Biotechnology), anti-PGC-1α (1:1000; Abcam), anti-TFAM (1:1000; Abcam), anti-NRF1 (1:1000; Abcam), anti-Cox4i1 (1:1000; Cusabio Biotech Co., Baltimore, MD, USA), anti-β-actin (1:1000), and anti-heat shock 70 kDa protein 8 (HSC70, 1:1000; Santa Cruz Biotechnology). The blots were reacted with peroxidase-conjugated secondary antibodies (Vector Laboratories, Inc., Burlingame, CA, USA), followed by an enhanced chemiluminescent sensitive plus reaction (BioFX Laboratories, Inc., Owings Mills,
Int. J. Mol. Sci. 2020, 21, 8246 MD, USA). The positive immunoreactive protein bands were detected by LAS-3000 film (FUJIFILM Corporation, Tokyo, Japan). Each blot density was normalized to β-actin or heat shock 70 kDa protein 8 and compared with that of each control.

4.9. Measurement of Cellular ROS

Cellular ROS production was measured using a fluorescence dye, dihydroethidium (DHE), as described [50]. Briefly, frozen kidney sections from the AKI mice treated with or without PP2 were used. DHE (5 mM, Molecular Probes, Eugene, Oregon, USA) was applied to the frozen sections of the kidneys (5 µm) for 10 min at 37 °C to obtain the presence of ROS with red fluorescence at 561 nm followed by DAPI staining, and images were taken by using a Zeiss ApoTome Axiovert 200M microscope (Carl Zeiss Microscopy).

4.10. Terminal Transferase-dUTP-Nick-End Labeling (TUNEL) Assay

Apoptosis was measured using the TUNEL assay according to the manufacturer’s protocol (Roche Diagnostics, Mannheim, Germany). Briefly, after deparaffinization and rehydration, kidney tissue sections were washed with 1× phosphate-buffered saline solution (PBS) and then incubated with TUNEL reaction mixture for 60 min at 37 °C in a humidified dark chamber. The sections were subsequently washed with 1× PBS (3 times), mounted with 4',6-diamidino-2-phenylindole, and images were taken using a Zeiss ApoTome Axiovert 200M microscope (Carl Zeiss Microscopy).

4.11. Measurement of Mitochondria

mProx cells were incubated with MitoTracker® probes stock solution (Molecular Probes) at 1 mM for 45 min. Cells were rinsed with PBS and then incubated with 3.7% formaldehyde at 37 °C for 15 min. For permeabilization, the cells were incubated with 0.2% Triton X-100 for 10 min. Images were taken using a Zeiss ApoTome Axiovert 200M microscope (Carl Zeiss Microscopy).

4.12. Statistical Analyses

All results are expressed as the mean ± SE. Analysis of variance (ANOVA) was used to assess the differences between multiple groups followed by Fisher’s least significant difference (LSD) test. The level of statistical significance was set at p values less than 0.05.

5. Conclusions

In summary, this study demonstrated that inhibition of SFK with PP2 ameliorated dysregulation of mitochondrial fitness in LPS-induced AKI. In particular, only Fyn and Src, not other SFK, were increased in LPS-induced AKI and were decreased by PP2. Furthermore, pretreatment with PP2 ameliorated the kidney injury including the inflammation, oxidative stress, and dysregulated mitochondrial biogenesis in LPS-induced AKI. These findings suggest that inhibition of SFK, specifically Fyn and Src, can be a potential preventive strategy in AKI, possibly via preserving mitochondrial biogenesis (Figure 8).
Figure 8. Schematic diagram illustrating that SFK activation affects mitochondrial biogenesis in LPS-induced AKI mice. The SFK inhibitor, PP2, suppressed inflammation and oxidative stress and improved mitochondrial biogenesis in the LPS-induced AKI mice.

Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/21/8246/s1.

Author Contributions: M.J.U. and H.H. were involved in the conception and design of the experiments; E.S.P. and M.J.U. contributed to performing the experiments; E.S.P. analyzed the data; E.S.P. and M.J.U. contributed to drafting the article or revising it; M.J.U. and H.H. provided intellectual content of critical importance to the work described; H.H. was responsible for the final approval of the version to be published. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by National Research Foundation grants (No. 2017R1D1A1B03028835 and 2020R1I1A1A01072879) and RP-Grant 2020 of Ewha Womans University, Korea. The Nox2 and Nox4 antibodies were kind gifts from Yun Soo Bae, Department of Life Science, College of Natural Sciences, Ewha Womans University, Seoul, Korea.

Conflicts of Interest: The authors have no conflicting financial interests.

References
1. International Society of Nephrology. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2012, 2, 122–123. [CrossRef]
2. Lewington, A.J.; Cerda, J.; Mehta, R.L. Raising awareness of acute kidney injury: A global perspective of a silent killer. Kidney Int. 2013, 84, 457–467. [CrossRef] [PubMed]
3. Seller-Perez, G.; Mas-Font, S.; Perez-Calvo, C.; Villa-Diaz, P.; Celaya-Lopez, M.; Herrera-Gutierrez, M.E. Acute kidney injury: Renal disease in the ICU. Med. Intensiva 2016, 40, 374–382. [CrossRef] [PubMed]
4. He, L.; Wei, Q.; Liu, J.; Yi, M.; Liu, Y.; Liu, H.; Sun, L.; Peng, Y.; Liu, F.; Venkatachalam, M.A.; et al. AKI on CKD: Heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017, 92, 1071–1083. [CrossRef]
5. Conger, J.D. Recent advances in the understanding of acute kidney injury. *F1000Prime Rep.* 2014, 6, 83–88. [CrossRef]
6. Stasi, A.; Intini, A.; Divella, C.; Franzin, R.; Montemurro, E.; Grandaliano, G.; Ronco, C.; Fiaccadori, E.; Pertosa, G.B.; Gesualdo, L.; et al. Emerging role of Lipopolysaccharide binding protein in sepsis-induced acute kidney injury. *Nephrol. Dial. Transplant.* 2017, 32, 24–31. [CrossRef]
7. Peerapornratana, S.; Manrique-Caballero, C.L.; Gómez, H.; Kellum, J.A. Acute kidney injury from sepsis: Current concepts, epidemiology, pathophysiology, prevention and treatment. *Kidney Int.* 2019, 96, 1083–1099. [CrossRef]
8. Weissbord, S.D.; Palevsky, P.M. Design of clinical trials in acute kidney injury: Lessons from the past and future directions. *Semin. Nephrol.* 2016, 36, 42–52. [CrossRef]
9. Conger, J.D. Interventions in clinical acute renal failure: What are the data? *Am. J. Kidney Dis.* 1995, 26, 565–576. [CrossRef]
10. Thomas, S.M.; Brugge, J.S. Cellular functions regulated by Src family kinases. *Annu. Rev. Cell Dev. Biol.* 1997, 13, 513–609. [CrossRef]
11. Verma, R.; Wharram, B.; Kovari, I.; Kunkel, R.; Nihalani, D.; Wary, K.K.; Wiggins, R.C.; Killen, P.; Holzmann, L.B. Fyn binds to and phosphorylates the kidney slit diaphragm component Nephrin. *J. Biol. Chem.* 2003, 278, 20716–20723. [CrossRef] [PubMed]
12. Sen, B.; Johnson, F.M. Regulation of SRC family kinases in human cancers. *J. Signal Transduct.* 2011, 2011, 865819–865833. [CrossRef] [PubMed]
13. Wu, H.; Shi, Y.; Deng, X.; Su, Y.; Du, C.; Wei, J.; Ren, Y.; Wu, M.; Hou, Y.; Duan, H. Inhibition of c-Src/p38 MAPK pathway ameliorates renal tubular epithelial cells apoptosis in db/db mice. *Mol. Cell. Endocrinol.* 2015, 417, 27–35. [CrossRef]
14. Taniguchi, K.; Xia, L.; Goldberg, H.J.; Lee, K.W.; Shah, A.; Stavar, L.; Masson, E.A.; Momen, A.; Shikatani, E.A.; John, R.; et al. Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. *Diabetes* 2013, 62, 3874–3886. [CrossRef]
15. Seo, H.Y.; Jeon, J.H.; Jung, Y.A.; Jung, G.S.; Lee, E.J.; Choi, Y.K.; Park, K.G.; Choe, M.S.; Jang, B.K.; Kim, M.K.; et al. Fyn deficiency attenuates renal fibrosis by inhibition of phospho-STAT3. *Kidney Int.* 2016, 90, 1285–1297. [CrossRef] [PubMed]
16. Dorotea, D.; Lee, S.; Lee, S.J.; Lee, G.; Son, J.B.; Choi, H.G.; Ahn, S.M.; Ha, H. KF-1607, A Novel pan src kinase inhibitor, attenuates obstruction-induced tubulointerstitial fibrosis in mice. *Biomol. Ther.* 2020. [CrossRef] [PubMed]
17. Uddin, M.J.; Dorotea, D.; Pak, E.S.; Ha, H. Fyn kinase: A potential therapeutic target in acute kidney injury. *Biomol. Ther.* 2020, 28, 213–221. [CrossRef]
18. Xiong, C.; Zang, X.; Zhou, X.; Liu, L.; Masucci, M.V.; Tang, J.; Li, X.; Liu, N.; Bayliss, G.; Zhao, T.C.; et al. Pharmacological inhibition of Src kinase protects against acute kidney injury in a murine model of renal ischemia/reperfusion. *Oncotarget* 2017, 8, 31238–31253. [CrossRef]
19. McBride, H.M.; Neuspiel, M.; Wasiak, S. Mitochondria: More than just a powerhouse. *Curr. Biol.* 2006, 16, R551–R560. [CrossRef]
20. Osellame, L.D.; Blacker, T.S.; Duchen, M.R. Cellular and molecular mechanisms of mitochondrial function. *Best Pract. Res. Clin. Endocrinol. Metab.* 2012, 26, 711–723. [CrossRef]
21. Sanchis-Gomar, F.; Garcia-Gimenez, J.L.; Gomez-Cabrera, M.C.; Pallardo, F.V. Mitochondrial biogenesis in health and disease. Molecular and therapeutic approaches. *Curr. Pharm. Des.* 2014, 20, 5619–5633. [CrossRef]
22. Bhargava, P.; Schnellmann, R.G. Mitochondrial energetics in the kidney. *Nat. Rev. Nephrol.* 2017, 13, 629–646. [CrossRef]
23. Tran, M.; Parikh, S.M. Mitochondrial biogenesis in the acutely injured kidney. *Nephron Clin. Pract.* 2014, 127, 42–45. [CrossRef]
24. Sun, J.; Zhang, J.; Tian, J.; Virzi, G.M.; Digvijay, K.; Cueto, L.; Yin, Y.; Rosner, M.H.; Ronco, C. Mitochondria in Sepsis-Induced AKI. *J. Am. Soc. Nephrol.* 2019, 30, 1151–1161. [CrossRef]
25. Ventura-Clapier, R.; Garnier, A.; Veksler, V. Transcriptional control of mitochondrial biogenesis: The central role of PGC-1alpha. *Cardiovasc. Res.* 2008, 79, 208–217. [CrossRef] [PubMed]
26. Tran, M.; Tam, D.; Bardia, A.; Bhasin, M.; Rowe, G.C.; Kher, A.; Zsengeller, Z.K.; Akhavan-Sharif, M.R.; Khankin, E.V.; Saintgeniez, M.; et al. PGC-1alpha promotes recovery after acute kidney injury during systemic inflammation in mice. *J. Clin. Investig.* 2011, 121, 4003–4014. [CrossRef]
27. Tibaldi, E.; Brunati, A.M.; Massimino, M.L.; Stringaro, A.; Colone, M.; Agostinelli, E.; Arancia, G.; Toninello, A. Src-Tyrosine kinases are major agents in mitochondrial tyrosine phosphorylation. *J. Cell. Biochem.* 2008, 104, 840–849. [CrossRef]
28. Salvi, M.; Brunati, A.M.; Bordin, L.; La Rocca, N.; Clari, G.; Toninello, A. Characterization and location of Src-dependent tyrosine phosphorylation in rat brain mitochondria. *Biochim. Biophys. Acta* 2002, 1589, 181–195. [CrossRef]
29. Augereau, O.; Claverol, S.; Boudes, N.; Basurko, M.J.; Bonneu, M.; Rossignol, R.; Mazat, J.P.; Letellier, T.; Dachary-Prigent, J. Identification of tyrosine-phosphorylated proteins of the mitochondrial oxidative phosphorylation machinery. *Cell. Mol. Life Sci.* 2005, 62, 1478–1488. [CrossRef]
30. Hunter, C.A.; Koc, H.; Koc, E.C. c-Src kinase impairs the expression of mitochondrial OXPHOS complexes in liver cancer. *Cell. Signal.* 2020, 72, 109651–109662. [CrossRef]
31. Okutani, D.; Lodyga, M.; Han, B.; Liu, M. Src protein tyrosine kinase family and acute inflammatory responses. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2006, 291, L129–L141. [CrossRef]
32. Wang, J.; Zhuang, S. Src family kinases in chronic kidney disease. *Am. J. Physiol. Renal. Physiol.* 2017, 313, F721–F728. [CrossRef] [PubMed]
33. Plotnikov, E.Y.; Pevzner, I.B.; Zorova, L.D.; Chernikov, V.P.; Prusov, A.N.; Kireev, I.I.; Silachev, D.N.; Skulachev, V.P.; Zorov, D.B. Mitochondrial damage and mitochondria-targeted antioxidant protection in LPS-induced acute kidney injury. *Antioxidants* 2019, 8, 176. [CrossRef]
34. Arany, I.; Megyesi, J.K.; Kaneto, H.; Price, P.M.; Safirstein, R.L. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. *Am. J. Physiol. Renal. Physiol.* 2004, 287, F543–F549. [CrossRef]
35. Cardone, L.; Carlucci, A.; Affaitati, A.; Livigni, A.; DeCristofaro, T.; Garbi, C.; Varrone, S.; Ullrich, A.; Gottesman, M.E.; Avvedimento, E.V.; et al. Mitochondrial AKAP121 binds and targets protein tyrosine phosphatase D1, a novel positive regulator of src signaling. *Mol. Cell. Biol.* 2004, 24, 4613–4626. [CrossRef]
36. Itoh, S.; Lemay, S.; Osawa, M.; Che, W.; Duan, Y.; Tompkins, A.; Sheu, S.S.; Abe, J. Mitochondrial Dok-4 recruits Src kinase and regulates NF-kappaB activation in endothelial cells. *J. Biol. Chem.* 2005, 280, 26383–26396. [CrossRef] [PubMed]
37. Basile, D.P.; Anderson, M.D.; Sutton, T.A. Pathophysiology of acute kidney injury. *Compr. Physiol.* 2012, 2, 1303–1353. [CrossRef]
38. Kinsey, G.R.; Li, L.; Okusa, M.D. Inflammation in acute kidney injury. *Nephron Exp. Nephrol.* 2008, 109, e102–e107. [CrossRef]
39. Lennmyr, F.; Ericsson, A.; Gerwins, P.; Akterin, S.; Ahlström, H.; Terënt, A. Src family kinase-inhibitor PP2 reduces focal ischemic brain injury. *Acta Neurol. Scand.* 2004, 110, 175–179. [CrossRef]
40. Severgnini, M.; Takahashi, S.; Tu, P.; Perides, G.; Homer, R.J.; Jhung, J.W.; Bhavsar, D.; Cochran, B.H.; Simon, A.R. Inhibition of the Src and Jak kinases protects against lipopolysaccharide-induced acute lung injury. *Am. J. Respir. Crit. Care Med.* 2005, 171, 858–867. [CrossRef] [PubMed]
41. Giannoni, E.; Buricchi, F.; Raugei, G.; Ramponi, G.; Chiarugi, P. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. *Mol. Cell. Biol.* 2005, 25, 6391–6403. [CrossRef]
42. Giannoni, E.; Chiarugi, P. Redox circuitries driving Src regulation. *Antioxid. Redox Signal.* 2014, 20, 2011–2025. [CrossRef]
43. Chowdhury, A.K.; Watkins, T.; Parinandi, N.L.; Saatian, B.; Kleinberg, M.E.; Usatyuk, P.V.; Natarajan, V. Src-mediated tyrosine phosphorylation of p47phox in hyperoxia-induced activation of NADPH oxidase and generation of reactive oxygen species in lung endothelial cells. *J. Biol. Chem.* 2005, 280, 20700–20711. [CrossRef]
44. Takikita-Suzuki, M.; Haneda, M.; Sasahara, M.; Owada, M.K.; Nakagawa, T.; Isono, M.; Takikita, S.; Koya, D.; Ogasawara, K.; Kikkawa, R. Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury. *Am. J. Pathol.* 2003, 163, 277–286. [CrossRef]
45. Płocinikowska, A.; Hromada-Judycka, A.; Borzęcka, K.; Kwiatkowska, K. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. *Cell. Mol. Life Sci.* 2015, 72, 557–581. [CrossRef] [PubMed]
46. Gong, P.; Angelini, D.J.; Yang, S.; Xia, G.; Cross, A.S.; Mann, D.; Bannerman, D.D.; Vogel, S.N.; Goldblum, S.E. TLR4 signaling is coupled to SRC family kinase activation, tyrosine phosphorylation of zonula adherens proteins, and opening of the paracellular pathway in human lung microvascular endothelia. *J. Biol. Chem.* 2008, 283, 13437–13449. [CrossRef]

47. Sohn, M.; Kim, K.; Uddin, M.J.; Lee, G.; Hwang, I.; Kang, H.; Kim, H.; Lee, J.H.; Ha, H. Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: The possible role of AMPK autophagy. *Am. J. Physiol. Renal. Physiol.* 2017, 312, F323–F334. [CrossRef]

48. Ha, H.; Yu, M.R.; Kim, K.H. Melatonin and taurine reduce early glomerulopathy in diabetic rats. *Free Radic. Biol. Med.* 1999, 26, 944–950. [CrossRef]

49. Kwon, G.; Uddin, M.J.; Lee, G.; Jiang, S.; Cho, A.; Lee, J.H.; Lee, S.R.; Bae, Y.S.; Moon, S.H.; Lee, S.J.; et al. A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: Possible role of peroxisomal and mitochondrial biogenesis. *Oncotarget* 2017, 8, 74217–74232. [CrossRef]

50. Uddin, M.J.; Pak, E.S.; Ha, H. Carbon monoxide releasing molecule-2 protects mice against acute kidney injury through inhibition of ER stress. *Korean J. Physiol. Pharmacol.* 2018, 22, 567–575. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).